Insite Vision Inc. (INSV) news stock charts
Insite Vision Inc. (INSV/INSV.OB) Investment Summary:
InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the treatment of blepharoconjunctivitis, an infection of the eyelid and the conjunctiva, as well as other ophthalmic infections; and ISV-405, a preclinical development candidate for the treatment of ocular infection. InSite Vision Incorporated has collaborative, licensing, and service agreements with Shin Poong Pharm Co., Ltd.; Bioceutica S.A.; Biem Pharmaceuticals; Essex Bio-Technology; Pfizer Inc. and Pfizer Products, Inc.; and Inspire Pharmaceuticals, Inc.; Catalent Pharma Solutions; and Bausch and Lomb Incorporated. The company was founded in 1986 and is based in Alameda, California.www.insitevision.com
Founded in 1986
INSITE VISION INC (INSV:OTC Bulletin Board Market)
LAST $0.36 USD
CHANGE TODAY -0.01 -2.70%
VOLUME 20.6K
As of 8:10 PM 03/19/10 All times are local (Market data is delayed by at least 15 minutes).
Snapshot of INSITE VISION INC (INSV)
|
OPEN
$0.36
|
PREVIOUS CLOSE
$0.37
|
|
|
DAY HIGH
$0.37
|
DAY LOW
$0.36
|
|
|
52 WEEK HIGH
06/3/09 - $0.66
|
52 WEEK LOW
03/23/09 - $0.17
|
|
|
MARKET CAP
34.1M
|
AVERAGE VOLUME 10 D
92.5K
|
|
|
EPS TTM
$-0.12
|
SHARES OUTSTANDING
94.7M
|
|
|
INSV Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for INSITE VISION INC (INSV)
Insite Vision Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2009
03/9/2010
Insite Vision Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2009. For the quarter, the company's revenues were $3.5 million compared to $1.5 million in the fourth quarter of 2008. Revenues were primarily royalties from Inspire for sales of AzaSite. The royalties increase was driven by a 67% increase in AzaSite revenues and an increase in the royalty rate from 20% to 25% beginning in August 2009. Net loss was $2.0 million or $0.02 diluted per share, compared to a net loss of $8.6 million, or $0.09 diluted per share, in 2008. Income from operations was $502,000 against loss from operations of $6.13 million a year ago. For the year, the company's revenues were $9.8 million compared to $13.7 million for the same period in 2008. Net loss was $14.2 million, or $0.15 diluted per share, compared to a net loss of $21.3 million, or $0.23 diluted per share, in 2008. Loss from operations was $4.12 against $13.3 million a year ago.
Insite Vision Inc. to Report Q4, 2009 Results on 03/09/2010
03/3/2010
Insite Vision Inc. announced that they will report Q4, 2009 results on 03/09/2010
Insite Vision Inc., Q4 2009 Earnings Call, Mar-09-2010
03/3/2010
Insite Vision Inc., Q4 2009 Earnings Call, Mar-09-2010
Insite Vision Inc. financial resources
INSV Competitors
| Company | Last | Change |
| Curis Inc | $3.15 USD | -0.09 |
| Insmed Inc | $1.22 USD | +0.05 |
| Peregrine Pharmaceuticals Inc | $3.16 USD | +0.02 |
| Spectrum Pharmaceuticals Inc | $5.15 USD | -0.125 |
| Vical Inc | $3.69 USD | -0.15 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | INSV | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3.5x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
INSV |
||
|
INSV transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||
More Recent Financial News About Insite Vision Inc.
INSITE VISION INC Files SEC form 8-K, Change in Directors or Principal Officers
2010-03-18 03:19:28
Quote: INSITE VISION INCRequest a Trial to NEW EDGAR Online Pro
Form
8-K for
INSITE VISION INC
17-Mar-2010Change in Directors or Principal OfficersPrivacy PolicyAbout Our AdsTerms of ServiceCopyright/IP PolicySend FeedbackSEC
Filing data and information provided by EDGAR Online,
Inc.
(1-800-416-6651). All information provided "as is"
for informational purposes
only, not intended for trading purposes or advice.
Neither Yahoo! nor any of
independent providers is liable for any informational
errors, incom...Read article
INSITE VISION INC Files SEC form 10-K, Annual Report
2010-03-15 07:57:44
Quote: The secured notes payable are
non-recourse to InSite Vision Incorporated. When the AzaSite royalties received
for any quarter exceed the interest payments and certain expenses due that
quarter, the excess will be applied to the repayment of principal of the notes
until the notes have been paid in full. Any shortfall of interest payments from
the royalty payments will be paid out of the interest reserves. As of
December 31, 2009, no balance remained on the interest reserve. Further
shortfalls, if...Read article
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
2010-03-11 06:29:47
Quote: INSVNews) today reported financialresults for the full year and fourth quarter ended December 31, 2009.“2009 was a year of steady performance by InSite Vision in which weexecuted against our strategic objectives,†said Louis Drapeau, InSiteVision’s Chief Executive Officer. “We begin 2010 in a solid cashposition, having successfully conserved our financial assets. Inaddition, AzaSite sales are up through the efforts of our partnerInspire Pharmaceuticals and we have receiv...Read article
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
2010-03-10 06:19:42
Quote: INSVNews) today reported financialresults for the full year and fourth quarter ended December 31, 2009.“2009 was a year of steady performance by InSite Vision in which weexecuted against our strategic objectives,†said Louis Drapeau, InSiteVision’s Chief Executive Officer. “We begin 2010 in a solid cashposition, having successfully conserved our financial assets. Inaddition, AzaSite sales are up through the efforts of our partnerInspire Pharmaceuticals and we have receiv...Read article
Q4 2009 InSite Vision Incorporated Earnings Release - Time Not Supplied
2010-03-10 06:19:42
Quote: LTD.000728.SZTime Not SuppliedHENGDIAN GROUP DMEGC MAGNETICS CO002056.SZAfter Market CloseHOLOGRAM INDUSTRIESHOL.PATime Not SuppliedHONG YUAN SECURITIES000562.SZTime Not SuppliedHONGRUN CONSTRUCTION GROUP CO LTD002062.SZAfter Market CloseHUAGONG TECH CO000988.SZTime Not SuppliedICF INTERNATIONAL INCICFIAfter Market CloseListenInmarsat plcISAT.LTime Not SuppliedInSite Vision IncorporatedINSV.OBTime Not SuppliedINTERIOR SERVICES GROUPISG.LTime Not SuppliedJ. Crew Group, Inc.JCGAfter Market CloseLi...Read article
InSite Vision to Report Fourth Quarter and Year-End 2009 Financial Results on March 9, 2010
2010-03-05 07:43:34
Quote: Press ReleaseSource: InSite Vision IncorporatedOn Wednesday March 3, 2010, 4:30 pm ESTALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB:- Company management will host a conference call beginning at 4:30 PMEST/1:30 PM PST to discuss results and review recent accomplishments.Investors can submit questions prior to the conference call via thecompany's website at The live conference call will also be webcast and available on theInvestor Relations page of the company's website at In...Read article
InSite Vision to Report Fourth Quarter and Year-End 2009 Financial Results on March 9, 2010
2010-03-04 06:18:32
Quote: All callers will need to enter theaccount number 286 and conference ID 346211.www.insitevision.com.A press release detailing fourth quarter and year-end 2009 financialresults will also be posted to the company's website and furnished tothe Securities and Exchange Commission on a Form 8-K prior to theconference call described above.About InSite VisionInSite Vision is committed to advancing new and superior ophthalmologicproducts for unmet eye care needs. InSite Vision is recognized for thediscove...Read article
InSite Vision Announces Webcast for Upcoming Annual Meeting of Stockholders
2010-02-26 03:49:08
Quote: Pacific Time on Wednesday, December 16, 2009.www.insitevision.comwww.insitevision.comthrough the "Information Request" tab on the Investor Relations page.About InSite VisionInSite Vision is committed to advancing new and superior ophthalmologicproducts for unmet eye care needs. InSite Vision is recognized for thediscovery and development of novel ocular pharmaceutical products basedon its DuraSite® bioadhesive polymer core technology, an innovativeplatform that extends the duration of drug de...Read article
InSite Vision to Advance New Ocular Anti-Inflammatory Candidate
2010-02-26 03:49:07
Quote: InSite Vision formulated a lower concentration of bromfenacwith its proprietary DuraSite® technology to create a proprietarytherapeutic product. InSite Vision intends to advance ISV-303 intoclinical studies pending the completion of Investigational NewDrug-enabling toxicology studies in the first half of 2010.“ISV-303 uses a lower concentration of an approved product and combinesit with a commercially-proven technology to create a promisingtherapeutic that we believe will offer signific...Read article
InSite Vision 2009 Annual Meeting scheduled for 1:00 pm ET today
2010-01-13 02:05:33
Quote: Call DetailsInSite Vision 2009 Annual MeetingWed,
Dec 16, 2009, 1:00 pm EasternAbout InSite Vision Inc.INSV.OB)InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a) clinical trial for the trea...Read article
InSite Vision to Advance New Ocular Anti-Inflammatory Candidate
2009-12-23 02:09:01
Quote: InSite Vision formulated a lower concentration of bromfenacwith its proprietary DuraSite® technology to create a proprietarytherapeutic product. InSite Vision intends to advance ISV-303 intoclinical studies pending the completion of Investigational NewDrug-enabling toxicology studies in the first half of 2010.“ISV-303 uses a lower concentration of an approved product and combinesit with a commercially-proven technology to create a promisingtherapeutic that we believe will offer signific...Read article
Goodman named to Texas drug company board
2009-12-23 02:09:00
Quote: executive Corey Goodman and two others — including the chairman of Alameda's InSite Vision — will join the board of Mirna Therapeutics Inc. as external directors.Austin, Texas-based Mirna said Goodman as well as Christopher Earl, the first president of nonprofit drug development company BIO Ventures for Global Health, and PTV Sciences founder Evan Melrose would join Mirna President and CEO Paul Lammers and founder Matt Winkler on the board.The appointments come one week after Mir...Read article
InSite Vision Announces Webcast for Upcoming Annual Meeting of Stockholders
2009-12-11 03:00:18
Quote: Pacific Time on Wednesday, December 16, 2009.www.insitevision.comwww.insitevision.comthrough the "Information Request" tab on the Investor Relations page.About InSite VisionInSite Vision is committed to advancing new and superior ophthalmologicproducts for unmet eye care needs. InSite Vision is recognized for thediscovery and development of novel ocular pharmaceutical products basedon its DuraSite® bioadhesive polymer core technology, an innovativeplatform that extends the duration of drug de...Read article
INSITE VISION INC Files SEC form 10-Q, Quarterly Report
2009-11-30 03:17:52
Quote: We undertake no obligation to update any
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence or identification of unanticipated events.
The following discussion should be read in conjunction with the unaudited
condensed consolidated financial statements and notes thereto included in this
Quarterly Report and in our Annual Report on Form 10-K for the year ended
December 31, 2008.
Overview
InSite Vision Incorporated ("we," &q...Read article
AzaSite® Production Increased in Response to Erythromycin Ophthalmic Ointment Shortage
2009-11-30 03:17:51
Quote: AzaSite isformulated with InSite Vision’s patented DuraSite® technology to enhancethe retention time of the therapeutic agents on the surface of the eyeleading to increased ocular tissue concentrations. InSite Vision andInspire Pharmaceuticals entered into a licensing agreement for thecommercialization of AzaSite in February 2007.About AzaSite®Staphylococcus aureus, Streptococcus mitisgroup, Streptococcus pneumoniae, and Haemophilus influenzae.Important Safety Information: www.azasi...Read article
InSite Vision to Report Financial Results for the Third Quarter on November 11, 2009
2009-11-30 03:17:50
Quote: All callers will need to enter theaccount number 286 and conference ID 336735.www.insitevision.com.A press release detailing third quarter 2009 financial results will alsobe posted to the company's website and furnished to the Securities andExchange Commission on a Form 8-K prior to the conference call describedabove.About InSite VisionInSite Vision is committed to advancing new and superior ophthalmologicproducts for unmet eye care needs. InSite Vision is recognized for thediscovery and develop...Read article
InSite Vision to Hold Annual Meeting of Stockholders
2009-11-30 03:17:50
Quote: The Annual Meeting will be held at thecompany’s headquarters at 965 Atlantic Avenue, Alameda, California.InSite Vision will mail the definitive proxy statement for the AnnualMeeting, as well as its annual report, in early November.About InSite VisionInSite Vision is committed to advancing new and superior ophthalmologicproducts for unmet eye care needs. InSite Vision is recognized for thediscovery and development of novel ocular pharmaceutical products basedon its DuraSite® bioadhesive...Read article
InSite Vision Reports Third Quarter 2009 Financial Results
2009-11-30 03:17:49
Quote: Total revenue for thethird quarter of 2009 was $2.2 million with a net loss of $3.1 million,or $0.03 per share.“We completed the third quarter with a solid cash position and increasedproduct revenues,†said Louis Drapeau, InSite Vision’s Chief ExecutiveOfficer. “AzaSite sales have been growing steadily through the effortsof our partner Inspire Pharmaceuticals, and beginning in the thirdquarter, our royalty rate on AzaSite increased by five percent to 25percent. In additi...Read article
Q3 2009 InSite Vision Incorporated Earnings Release - Time Not Supplied
2009-11-30 03:17:49
Quote: Read article
InSite Vision Third Quarter Fiscal Year 2009 Financial Results Call scheduled for 4:30 pm ET today
2009-11-30 03:17:48
Quote: Call DetailsInSite Vision Third Quarter Fiscal Year 2009 Financial ResultsWed,
Nov 11, 2009, 4:30 pm EasternAbout InSite Vision Inc.INSV.OB)InSite Vision Incorporated operates as an ophthalmic product development company in the United States. It engages in the development and commercialization of ophthalmic pharmaceutical products based on DuraSite drug delivery technology. The company offers AzaSite for the treatment of bacterial conjunctivitis. It develops ISV-502, which completed Phase III (a...Read article
Would you like to leave a comment about Insite Vision Inc. INSV/INSV.OB
Find out what social network information about Insite Vision Inc. are available on RealpenniesWorst 5 - Click here to find out what stocks have been voted down by our visitors and users
Besides Insite Vision Inc.'s Stock there is more great penny stock and market information at Realpennies